Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Editorial
Nature Reviews Drug Discovery 5, 525 (1 July 2006) | doi:10.1038/nrd2102
Keeping sight of the goal
Abstract
The call by the World Health Organization for all clinical trials to be registered, and for information to be fully disclosed at the time of registration, has antagonized the pharmaceutical industry. More pragmatism could be needed if the important initiative to improve the transparency of clinical research is to maintain momentum.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
